Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology (NASDAQ: PBYI) announced the approval of an inducement restricted stock unit award for a new non-executive employee. The award, covering 7,500 shares of Puma common stock, was granted under the company's 2017 Employment Inducement Incentive Award Plan. The stock units will vest over three years, with one-third vesting on December 1, 2025, and one-sixth vesting every six months thereafter, contingent on continued employment. This grant complies with Nasdaq Listing Rule 5635(c)(4) as an employment inducement.
Puma Biotechnology (NASDAQ: PBYI) ha annunciato l'approvazione di un premio in azioni riservate come incentivo per un nuovo dipendente non esecutivo. Il premio, che riguarda 7.500 azioni comuni di Puma, è stato concesso nell'ambito del Piano di Incentivazione per l'Assunzione del 2017. Le unità azionarie maturinganno in tre anni, con un terzo che maturerà il 1° dicembre 2025, e un sesto che maturerà ogni sei mesi successivamente, soggetto a continua occupazione. Questo premio è conforme alla Regola di Quotazione Nasdaq 5635(c)(4) come incentivo all'impiego.
Puma Biotechnology (NASDAQ: PBYI) anunció la aprobación de una concesión de unidades de acciones restringidas como incentivo para un nuevo empleado no ejecutivo. La concesión, que abarca 7,500 acciones comunes de Puma, se otorgó bajo el Plan de Incentivos de Empleo de 2017. Las unidades de acciones se adquirirán durante tres años, con un tercio adquiriéndose el 1 de diciembre de 2025, y un sexto adquiriéndose cada seis meses a partir de entonces, condicionado a la continuidad del empleo. Esta concesión cumple con la Regla de Cotización 5635(c)(4) de Nasdaq como incentivo de empleo.
푸마 바이오테크놀로지 (NASDAQ: PBYI)는 새로운 비임원 직원에 대한 유도 제한 주식단위 보상의 승인을 발표했습니다. 이 보상은 7,500주의 푸마 보통주를 포함하며, 2017년 취업 유도 인센티브 보상 계획에 따라 제공되었습니다. 주식 단위는 3년에 걸쳐 상환되며, 2025년 12월 1일에 1/3이 상환되고 그 이후로는 6개월마다 1/6이 상환되며, 지속적인 고용에 따라 달라집니다. 이 보상은 고용 유도로서 나스닥 상장 규칙 5635(c)(4)를 준수합니다.
Puma Biotechnology (NASDAQ: PBYI) a annoncé l'approbation d'une attribution d'unités d'actions restreintes incitatives pour un nouvel employé non cadre. L'attribution, qui concerne 7 500 actions ordinaires de Puma, a été accordée dans le cadre du Plan d'Incentives à l'Emploi de 2017. Les unités d'actions seront acquises sur une période de trois ans, avec un tiers qui sera acquis le 1er décembre 2025, et un sixième qui sera acquis tous les six mois par la suite, sous réserve d'un emploi continu. Cette attribution est conforme à la règle de cotation Nasdaq 5635(c)(4) en tant qu'incitation à l'emploi.
Puma Biotechnology (NASDAQ: PBYI) hat die Genehmigung für eine Anreiz-Restaktieneinheitenauszeichnung für einen neuen nicht-executive Mitarbeiter bekannt gegeben. Die Auszeichnung umfasst 7.500 Aktien von Puma Stammaktien und wurde im Rahmen des Unternehmensplans für Beschäftigungsanreize von 2017 gewährt. Die Aktieneinheiten werden über drei Jahre schrittweise erworben, wobei ein Drittel am 1. Dezember 2025 und ein Sechstel alle sechs Monate danach fällig wird, abhängig von einer fortgesetzten Beschäftigung. Diese Auszeichnung erfüllt die Nasdaq-Listingregel 5635(c)(4) als Beschäftigungsanreiz.
- None.
- None.
The award was granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit award vests over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award’s vesting commencement date, December 1, 2024, and one-sixth of the shares underlying the award vesting on each six-month anniversary of the vesting commencement date thereafter, subject to continued service. The award was granted as an inducement material to the new employee entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral), in 2011. Neratinib, oral was approved by the
In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA™-Lung1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive-stage small cell lung cancer. In November 2024, Puma initiated ALISCA™-Breast1, a Phase II clinical trial of alisertib in combination with endocrine therapy for the treatment of patients with HER2-negative, HR-positive metastatic breast cancer.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241204363283/en/
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com
Source: Puma Biotechnology, Inc.
FAQ
How many shares were granted in Puma Biotechnology's (PBYI) latest inducement award?
What is the vesting schedule for Puma Biotechnology's (PBYI) December 2024 inducement award?
Under which plan did Puma Biotechnology (PBYI) grant its December 2024 inducement award?
